Sotagliflozin is a Small Molecule owned by Lexicon Pharmaceuticals, and is involved in 43 clinical trials, which were completed.
Sotagliflozin acts by inhibiting SGLT1 and SGLT2. SGLT2-inhibiting compounds can potentially treat diabetes by increasing urinary glucose excretion, thereby lowering blood glucose levels. LX4211 through inhibition of SGLT2 has the potential to reduce caloric load and thereby enhance overall glucose homeostasis in patients with type 2 diabetes. SGLT1 is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney. SGLT2 inhibitors block the re-absorption of glucose from the kidney, SGLT1 inhibitors suppress absorption of glucose from the intestines.
The revenue for Sotagliflozin is expected to reach a total of $1.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Sotagliflozin NPV Report.
Sotagliflozin is originated and owned by Lexicon Pharmaceuticals.
Sotagliflozin (Zynquista) is a potential antihyperglycemic agent. It is formulated as film coated tablets for oral route of administration. Zynquista is indicated as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.
Sotagliflozin (LX4211, SAR-439954) is under development for the treatment of type 2 diabetes. It was also under development for the treatment of type 1 diabetes and worsening of heart failure in diabetic patients in the US.
Lexicon Pharmaceuticals Overview
Lexicon Pharmaceuticals (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. Under its Genome5000 program, the company studied nearly 5,000 genes and identified more than 100 protein targets with significant remedial potential in a range of diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin for heart failure and type 1 diabetes. Its clinical and preclinical development programs, LX2761 and LX9211, are meant for the treatment of diabetes and neuropathic pain, respectively. It has business collaborations with several pharmaceutical and biotechnology companies. The company operates an office in New Jersey and has a laboratory in Texas. Lexicon is headquartered at The Woodlands, Texas, the US.
The company reported revenues of (US Dollars) US$0.3 million for the fiscal year ended December 2021 (FY2021), a decrease of 98.8% over FY2020. The operating loss of the company was US$87.1 million in FY2021, compared to an operating loss of US$46.8 million in FY2020. The net loss of the company was US$87.8 million in FY2021, compared to a net loss of US$58.6 million in FY2020.
Quick View – Sotagliflozin
|Highest Development Stage|